“Oncologic Safety of Staged Pre-Pectoral Implant Reconstruction Following Nipple-Sparing Mastectomy: a Mean 9-Year Follow-Up.”

Abstract

repectoral reconstruction following therapeutic nipple-sparing mastectomy has been widely accepted as a better alternative to submuscular reconstruction. 1-3 Although short-term oncologic safety and advantages of prepectoral reconstruction are well documented, long-term oncologic follow-up more than 5 years has not been reported. 4,5 We previously reported our experience on the aesthetic/functional outcomes of therapeutic/prophylactic nipple-sparing mastectomy and prepectoral staged expander/implant reconstruction in 155 consecutive patients followed up for an average of 55.5 months. 6 In this article, we report on the oncologic outcome of 151 patients from the same group of patients after an average 109-month follow-up.The surgical technique of using mastectomy flaps that preserves the subcutaneous fat and its circulation to minimize skin complications and ensures the oncologic safety of the procedure is discussed. Because all reconstructions were

Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis

“…In a study from the Taiwan National Health Insurance Database looking including 39 216 patients reported a higher risk of EC (HR 3.74) in women under 50 years of age 12 . Although, currently is less common to prescribe 5 or 10 years of tamoxifen treatment for hormone receptor positive postmenopausal BC women with due to other preferred treatment strategies including aromatase inhibitors for 5 or more years, switch therapies with both aromatase inhibitors and tamoxifen, there are some premenopausal patients that are still candidates for tamoxifen treatment and also it is important to take in account that in basic resources settings tamoxifen is still the first choice of treatment in both pre and postmenopausal women 49,50 …”

“…12 Although, currently is less common to prescribe 5 or 10 years of tamoxifen treatment for hormone receptor positive postmenopausal BC women with due to other preferred treatment strategies including aromatase inhibitors for 5 or more years, switch therapies with both aromatase inhibitors and tamoxifen, there are some premenopausal patients that are still candidates for tamoxifen treatment and also it is important to take in account that in basic resources settings tamoxifen is still the first choice of treatment in both pre and postmenopausal women. 49,50 EC is the most common gynecologic malignancy in the Western world and the most important risk factor is estrogen exposure (endogenous or exogenous) such as nulliparity, early menarche and late menopause, obesity and estrogen medication. 51 Western women as well are those at a higher risk of tamoxifen associated EC according to our and other studies results.…”

Breast Cancer Oncological Outcomes at an Italian Center Following Nipple-Sparing and Skin-Sparing Mastectomy Techniques

“…The 5-year recurrence rate among women who underwent SSM and NSM in our population was respectively 7.8% and 13.3%. Despite the high variability in median follow-up lengths, in the literature recurrence rate of SSM and NSM range respectively from 0% to 14.3% [15,[25][26][27][28][29][30][31][32][33][34][35][36] and from 0% to 10.3% [25,32,34,35,[37][38][39].…”

Discussion: Oncologic Safety of Staged Prepectoral Implant Reconstruction following Nipple-Sparing Mastectomy: A Mean 9-Year Follow-Up

“…In this report, 1 Drs. Salibian and Harkness update their 2016 work 2 on “staged suprapectoral expander/implant reconstruction without acellular dermal matrix following nipple-sparing mastectomy.” In that article, they reported their experience with creating “thick flaps” in nipple-sparing mastectomy and challenged whether allograft was necessary to achieve good cosmetic outcomes in this clinical setting.…”